Clik here to view.
Astellas CEO talks future beyond Xtandi as Japanese drugmaker puts roots in...
CAMBRIDGE, MA — When looking to the future of the drug industry, the allure of Boston is strong. This week, the Japanese drugmaker Astellas became the latest company to open a research hub in the...
View ArticleNon-viral delivery startup Vesigen Therapeutics trims staff as it evaluates...
Cambridge, MA-based startup Vesigen Therapeutics is laying off staff and “evaluating strategic options,” CEO Paulash Mohsen confirmed to Endpoints News via email Friday afternoon. Multiple employees...
View ArticleFederal judge rejects pharma industry’s request to halt Maryland’s 340B law
A federal judge in Maryland has rejected a request from drugmakers and industry group PhRMA to stop a Maryland law that would lift restrictions on the amount of discounts directed at hospitals serving...
View ArticleExclusive: Influential Democrat will oppose Biosecure Act ahead of House vote
An influential member in Congress is slated to publicly disavow the closely watched Biosecure Act ahead of a planned House vote next week, according to a letter reviewed by Endpoints News. The...
View ArticleNotable shakeups this week; Recursion's mixed data; Eli Lilly's $1B bet; and...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleSummit presents Phase 3 lung cancer data beating Merck's Keytruda
A few months after Summit Therapeutics shocked the oncology world with an early claim that its lung cancer drug ivonescimab had beaten Merck’s Keytruda, it has backed up its talk with data. In the...
View ArticleEli Lilly invests in Superluminal's $120M Series A round as AI-focused...
Superluminal Medicines joined the ranks of AI-focused biotechs hauling in megarounds, closing an RA Capital-led $120 million Series A, the startup said Monday. The new funds should be sufficient to...
View ArticleTerns’ oral GLP-1 passes Phase 1 test with promising weight loss after one month
Terns Pharmaceuticals unveiled early-phase weight loss data from an oral GLP-1 agonist that it says could be more tolerable at higher doses than currently marketed GLP-1 drugs administered the same...
View ArticleClik here to view.
Relay Therapeutics reports positive PFS data for its PI3Kα inhibitor combo in...
Relay Therapeutics touted positive interim progression-free survival data for its PI3Kα inhibitor in heavily treated breast cancer patients. In the early-stage ReDiscover trial, Relay is investigating...
View ArticleMBX seeks $114M IPO to compete with Ascendis and get a long-acting GLP-1/GIP...
MBX Biosciences is the latest IPO contender after submitting its pitch for a $114 million Nasdaq debut, which will go toward three experimental drugs. The peptide drugmaker is working on treatments for...
View ArticleClik here to view.
Lilly again hires from within for CFO post, elevating 23-year company veteran
The world’s most valuable drugmaker has a new finance chief. Anat Ashkenazi Lucas Montarce stepped into the chief financial officer role at Eli Lilly, effective immediately Monday. He replaces Anat...
View ArticleClik here to view.
Merck, Daiichi Sankyo detail Phase 2 ADC results in small cell lung cancer,...
Mid-stage clinical trial results show why Merck and Daiichi Sankyo recently moved an antibody-drug conjugate from their $4 billion partnership into Phase 3 studies for an aggressive form of lung...
View ArticleInvestors pour $370M+ into Ken Song's autoimmune biotech after his RayzeBio...
Ken Song knows how to step on the gas pedal. His new company, called Candid Therapeutics, emerged from stealth on Monday morning with more than $370 million to its name and two clinical-stage T cell...
View ArticleBicycle Therapeutics makes an early case for its Padcev competitor: #ESMO24
Bicycle Therapeutics disclosed in an abstract Sunday that 45% of bladder cancer patients responded to its experimental treatment in an early-stage study. In 38 patients evaluated for efficacy, one saw...
View ArticleImmunovant shares mid-stage Graves’ disease data; FDA lifts Rezolute’s hold
Plus, news about Xencor, Bambusa Therapeutics, Grin Therapeutics and Vaxcyte: Immunovant reports Phase 2a Graves’ disease data: Patients taking batoclimab for 12 weeks saw a 76% response rate and an...
View ArticleAstraZeneca's monoclonal antibody misses primary endpoint in mid-stage trial...
AstraZeneca’s anti-IL-33 monoclonal antibody failed a Phase 2a study in chronic obstructive pulmonary disease, though the company noted there were still “encouraging clinical efficacy signals.” In the...
View Article#ESMO24 roundup: New data on Amgen’s PRMT5 inhibitor seem lackluster, and...
On Sunday evening, abstracts from the European Society for Medical Oncology were released. While some of oncology’s most exciting recent data were reported a week before at a separate conference, ESMO...
View ArticleZealand’s GLP-1/GLP-2 drug bounces back with new Phase 1b data
Zealand Pharma’s GLP-1/GLP-2 receptor dual agonist showed promising weight loss in an early-stage trial after a previous effort with lower doses ended with “underwhelming” efficacy. In part one of the...
View ArticleClik here to view.
AstraZeneca, Gilead detail TROP2 ADC data in lung cancer as they search for...
AstraZeneca is focusing on a subgroup of lung cancer patients as it seeks a path to approval for its TROP2-directed antibody-drug conjugate, which earlier this year failed to hit the goal of improving...
View ArticleClik here to view.
GSK says long-acting asthma hopeful significantly cut attacks
GSK said Monday that its projected asthma blockbuster depemokimab reduced asthma attacks by 54% in two large Phase 3 trials, but missed some secondary endpoints. The company teased the results in May,...
View Article